UPCC 09220: Phase II Study of Telomelysin (OBP-301) in Combination with Pembrolizumab in Esophagogastric Adenocarcinoma
Brief description of study
The purpose of this study is to test the effects of the research study drug Telomelysin (OBP-301) in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer. Eligible subjects are those with advanced or metastatic cancer of the stomach or junction between the stomach and esophagus.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
gastroesophageal junction cancer, stomach cancer
-
Age: - 99 Years
-
Gender: All
Updated on
17 Oct 2020.
Study ID: 843696
